Effects of renal denervation on insulin resistance

Dagmara Hering, Murray D. Esler, Markus P. Schlaich

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Hypertension and diabetes are recognized as two major comorbidities accounting for the greatest proportion of cardiovascular morbidity and mortality. Despite the availability of safe and effective pharmacological therapies, the percentage of patients achieving optimal blood pressure and glycemic control remains unsatisfactory. The contribution of sympathetic activation to the development and maintenance of systemic hypertension and comorbidities is well recognized. Aside from several novel pharmacological approaches, catheter-based sympathetic renal denervation (RDN) has gained a significant role in treatment-resistant hypertension and has recently been introduced to clinical practice. Preliminary data indicate that aside from better blood pressure control, RDN may also be associated with a reduction in fasting glucose and insulin levels, as well as improvements in the Homeostasis Model Assessment (HOMA) index. If these observations are confirmed in larger controlled clinical trials, RDN may emerge as a preferred treatment option for patients with resistant hypertension and concomitant alterations of glucose metabolism.

Original languageEnglish
Pages (from-to)1381-1386
Number of pages6
JournalExpert Review of Cardiovascular Therapy
Volume10
Issue number11
DOIs
Publication statusPublished - 1 Nov 2012
Externally publishedYes

Fingerprint

Denervation
Insulin Resistance
Hypertension
Kidney
Comorbidity
Pharmacology
Blood Pressure
Glucose
Sympathectomy
Controlled Clinical Trials
Fasting
Homeostasis
Therapeutics
Catheters
Maintenance
Insulin
Morbidity
Mortality

Cite this

Hering, Dagmara ; Esler, Murray D. ; Schlaich, Markus P. / Effects of renal denervation on insulin resistance. In: Expert Review of Cardiovascular Therapy. 2012 ; Vol. 10, No. 11. pp. 1381-1386.
@article{43f6795f67fa4614b3e70122f99d4cb6,
title = "Effects of renal denervation on insulin resistance",
abstract = "Hypertension and diabetes are recognized as two major comorbidities accounting for the greatest proportion of cardiovascular morbidity and mortality. Despite the availability of safe and effective pharmacological therapies, the percentage of patients achieving optimal blood pressure and glycemic control remains unsatisfactory. The contribution of sympathetic activation to the development and maintenance of systemic hypertension and comorbidities is well recognized. Aside from several novel pharmacological approaches, catheter-based sympathetic renal denervation (RDN) has gained a significant role in treatment-resistant hypertension and has recently been introduced to clinical practice. Preliminary data indicate that aside from better blood pressure control, RDN may also be associated with a reduction in fasting glucose and insulin levels, as well as improvements in the Homeostasis Model Assessment (HOMA) index. If these observations are confirmed in larger controlled clinical trials, RDN may emerge as a preferred treatment option for patients with resistant hypertension and concomitant alterations of glucose metabolism.",
keywords = "diabetes, hypertension, insulin resistance, obesity, renal denervation, sympathetic activity",
author = "Dagmara Hering and Esler, {Murray D.} and Schlaich, {Markus P.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1586/erc.12.140",
language = "English",
volume = "10",
pages = "1381--1386",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews",
number = "11",

}

Effects of renal denervation on insulin resistance. / Hering, Dagmara; Esler, Murray D.; Schlaich, Markus P.

In: Expert Review of Cardiovascular Therapy, Vol. 10, No. 11, 01.11.2012, p. 1381-1386.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Effects of renal denervation on insulin resistance

AU - Hering, Dagmara

AU - Esler, Murray D.

AU - Schlaich, Markus P.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Hypertension and diabetes are recognized as two major comorbidities accounting for the greatest proportion of cardiovascular morbidity and mortality. Despite the availability of safe and effective pharmacological therapies, the percentage of patients achieving optimal blood pressure and glycemic control remains unsatisfactory. The contribution of sympathetic activation to the development and maintenance of systemic hypertension and comorbidities is well recognized. Aside from several novel pharmacological approaches, catheter-based sympathetic renal denervation (RDN) has gained a significant role in treatment-resistant hypertension and has recently been introduced to clinical practice. Preliminary data indicate that aside from better blood pressure control, RDN may also be associated with a reduction in fasting glucose and insulin levels, as well as improvements in the Homeostasis Model Assessment (HOMA) index. If these observations are confirmed in larger controlled clinical trials, RDN may emerge as a preferred treatment option for patients with resistant hypertension and concomitant alterations of glucose metabolism.

AB - Hypertension and diabetes are recognized as two major comorbidities accounting for the greatest proportion of cardiovascular morbidity and mortality. Despite the availability of safe and effective pharmacological therapies, the percentage of patients achieving optimal blood pressure and glycemic control remains unsatisfactory. The contribution of sympathetic activation to the development and maintenance of systemic hypertension and comorbidities is well recognized. Aside from several novel pharmacological approaches, catheter-based sympathetic renal denervation (RDN) has gained a significant role in treatment-resistant hypertension and has recently been introduced to clinical practice. Preliminary data indicate that aside from better blood pressure control, RDN may also be associated with a reduction in fasting glucose and insulin levels, as well as improvements in the Homeostasis Model Assessment (HOMA) index. If these observations are confirmed in larger controlled clinical trials, RDN may emerge as a preferred treatment option for patients with resistant hypertension and concomitant alterations of glucose metabolism.

KW - diabetes

KW - hypertension

KW - insulin resistance

KW - obesity

KW - renal denervation

KW - sympathetic activity

UR - http://www.scopus.com/inward/record.url?scp=84871302177&partnerID=8YFLogxK

U2 - 10.1586/erc.12.140

DO - 10.1586/erc.12.140

M3 - Review article

VL - 10

SP - 1381

EP - 1386

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 11

ER -